Efavirenz News and Research

RSS
Efavirenz, also known as EFV or Sustiva, is a type of medicine called a non-nucleoside reverse transcriptase inhibitor (NNRTI). NNRTIs block reverse transcriptase, a protein that HIV needs to make more copies of itself. Efavirenz was approved by the FDA on September 17, 1998, for use with other antiretroviral agents in the treatment of HIV infection in adults and children ages 3 and older. This medicine does not cure HIV infection or AIDS and does not reduce the risk of passing the virus to other people. Efavirenz may also be used with other antiretroviral medications to prevent HIV in people who have been exposed to the virus in the work place, such as health care providers who come in contact with HIV infected blood through an accidental needle stick.
The role of brain cells in spreading HIV

The role of brain cells in spreading HIV

Newer antiretroviral drugs may be the safest, most effective HIV treatment during pregnancy

Newer antiretroviral drugs may be the safest, most effective HIV treatment during pregnancy

Children born to women on HIV therapy more likely to have microcephaly, developmental delays

Children born to women on HIV therapy more likely to have microcephaly, developmental delays

New research may help treat HIV patients without elevating risk for liver disease

New research may help treat HIV patients without elevating risk for liver disease

Low doses of anti-HIV drug appear to reduce tau protein in neurons of Alzheimer’s patients

Low doses of anti-HIV drug appear to reduce tau protein in neurons of Alzheimer’s patients

NIH launches large study to compare treatments for pregnant women with HIV

NIH launches large study to compare treatments for pregnant women with HIV

U.S. FDA approves updated labeling for pan-genotypic single tablet regimen for HCV/HIV co-infected patients

U.S. FDA approves updated labeling for pan-genotypic single tablet regimen for HCV/HIV co-infected patients

Cholesterol-processing enzyme could be therapeutic target to stave off neurologic diseases

Cholesterol-processing enzyme could be therapeutic target to stave off neurologic diseases

New trial examines use of nanotechnology to improve delivery of drugs to HIV patients

New trial examines use of nanotechnology to improve delivery of drugs to HIV patients

Added benefit of combination drug for HIV-infected patients not proven

Added benefit of combination drug for HIV-infected patients not proven

Tiny doses of anti-HIV drug may be effective for treating Alzheimer's disease

Tiny doses of anti-HIV drug may be effective for treating Alzheimer's disease

Nearly half of newly-infected HIV patients experience neurologic issues

Nearly half of newly-infected HIV patients experience neurologic issues

Study evaluates effectiveness of antiretroviral treatment in HIV-infected children

Study evaluates effectiveness of antiretroviral treatment in HIV-infected children

Nurse-trainer uses new approach to teach correct combination of HIV drugs to Angola's nurses

Nurse-trainer uses new approach to teach correct combination of HIV drugs to Angola's nurses

FDA approves AbbVie's VIEKIRA PAK for treatment of patients with GT1 HCV infection

FDA approves AbbVie's VIEKIRA PAK for treatment of patients with GT1 HCV infection

MSD announces Phase 2b results of doravirine therapy in untreated patients with HIV-1 infection

MSD announces Phase 2b results of doravirine therapy in untreated patients with HIV-1 infection

FDA approves ViiV Healthcare's Triumeq tablets for treatment of HIV-1 infection

FDA approves ViiV Healthcare's Triumeq tablets for treatment of HIV-1 infection

Merck enrolls first patient in reformulated raltegravir Phase 3 trial for treatment of HIV-1 infection

Merck enrolls first patient in reformulated raltegravir Phase 3 trial for treatment of HIV-1 infection

Dolutegravir drug offers added benefit in HIV patients

Dolutegravir drug offers added benefit in HIV patients

Janssen submits sNDA to FDA for simeprevir in combination with sofosbuvir for treatment of HCV genotype 1 infection

Janssen submits sNDA to FDA for simeprevir in combination with sofosbuvir for treatment of HCV genotype 1 infection